PLC6 Antibody

LRP6 Antibody Development and Function

A study in Molecular Biology of the Cell describes the generation of a highly specific monoclonal antibody (clone 1C10) targeting LRP6, a receptor critical in the Wnt/β-catenin signaling pathway . Key findings include:

• Specificity: The antibody binds endogenous LRP6 with minimal cross-reactivity to LRP5, as confirmed by Western blotting and immunoprecipitation .

• Cellular Localization: LRP6 exists as a glycosylated dimer at the cell surface, essential for Wnt signal transduction .

• Regulatory Insights: Wnt signaling negatively regulates LRP6 mRNA levels, suggesting a feedback mechanism .

Potential Confusion with CLDN6 Antibodies

CLDN6 Antibodies: Therapeutic Potential and Challenges

A study in Science highlights the development of anti-CLDN6 mAbs with picomolar affinity and minimal cross-reactivity to CLDN9 or other claudins . Key insights:

• Target Specificity: CLDN6 is overexpressed in cancer cells but minimally expressed in healthy tissues, making it a candidate for targeted therapy .

• Structural Basis: Atomic-level mapping revealed that anti-CLDN6 mAbs bind to a unique γ-carbon contact at residue Q156, distinguishing CLDN6 from CLDN9 .

4. General Antibody Development Strategies
While no direct data on "PLC6 Antibody" exists, methodologies from related studies provide a framework for antibody development:

Screening and Validation

• Hybridoma Screening: Immunization with recombinant antigens (e.g., LRP6 cytoplasmic domain) followed by ELISA and functional assays (e.g., hemolysis inhibition) .

• Epitope Mapping: Structural techniques (e.g., X-ray crystallography) identify critical residues for binding specificity .

Functional Characterization

• In Vitro Assays:

  • Immunoprecipitation: Confirms target protein interactions .

  • Cell Surface Biotinylation: Validates membrane localization .

• In Vivo Models:

  • Mouse Studies: Assess efficacy in disease models (e.g., hemolysis prevention in PNH patients) .